BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 14634511)

  • 1. Occult breast carcinoma presenting with axillary lymph node metastases: follow-up of eleven patients.
    Matsuoka K; Ohsumi S; Takashima S; Saeki T; Aogi K; Mandai K
    Breast Cancer; 2003; 10(4):330-4. PubMed ID: 14634511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Occult breast carcinoma presenting with axillary lymph node metastases: a follow-up study of 48 patients.
    Rosen PP; Kimmel M
    Hum Pathol; 1990 May; 21(5):518-23. PubMed ID: 2338331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
    Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
    Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Serous cystadenocarcinoma of the ovary with simultaneous breast metastases. Description of a case].
    Manini C; Pietribiasi F; Sapino A; Donadio S
    Pathologica; 1998 Apr; 90(2):152-5. PubMed ID: 9619059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential sensitivity of estrogen/progesterone receptors and BRST-2 markers in metastatic ductal and lobular breast carcinoma to the skin.
    Wallace ML; Smoller BR
    Am J Dermatopathol; 1996 Jun; 18(3):241-7. PubMed ID: 8806958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Invasive micropapillary carcinoma of the breast: high incidence of lymph node metastasis with extranodal extension and its immunohistochemical profile compared with invasive ductal carcinoma.
    Zekioglu O; Erhan Y; Ciris M; Bayramoglu H; Ozdemir N
    Histopathology; 2004 Jan; 44(1):18-23. PubMed ID: 14717664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Solid papillary carcinoma of the breast: A special entity needs to be distinguished from conventional invasive carcinoma avoiding over-treatment.
    Guo S; Wang Y; Rohr J; Fan C; Li Q; Li X; Wang Z
    Breast; 2016 Apr; 26():67-72. PubMed ID: 27017244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical analysis of pleomorphic lobular carcinoma: higher expression of p53 and chromogranin and lower expression of ER and PgR.
    Radhi JM
    Histopathology; 2000 Feb; 36(2):156-60. PubMed ID: 10672061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Factors on the Positivity for Metastases of the Axillary Lymph Nodes from Primary Breast Cancer.
    Kondov B; Kondov G; Spirovski Z; Milenkovikj Z; Colanceski R; Petrusevska G; Pesevska M
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2017 Mar; 38(1):81-90. PubMed ID: 28593885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of neoadjuvant chemotherapy in occult breast cancer: Five case reports.
    Yang H; Li L; Zhang M; Zhang S; Xu S; Ma X
    Medicine (Baltimore); 2017 Oct; 96(40):e8200. PubMed ID: 28984771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunohistochemical comparison between GCDFP-15 and estrogen and progesterone receptors in the diagnosis of metastatic carcinoma of the breast].
    Villarroel Salinas J; Ortiz Hidalgo C; Soria Céspedes D
    Gac Med Mex; 2012; 148(3):213-7. PubMed ID: 22820353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen and progesterone receptors and anti-gross cystic disease fluid protein 15 (BRST-2) fail to distinguish metastatic breast carcinoma from eccrine neoplasms.
    Wallace ML; Longacre TA; Smoller BR
    Mod Pathol; 1995 Dec; 8(9):897-901. PubMed ID: 8751328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. E-cadherin immunohistochemical analysis of histiocytoid carcinoma of the breast.
    Gupta D; Croitoru CM; Ayala AG; Sahin AA; Middleton LP
    Ann Diagn Pathol; 2002 Jun; 6(3):141-7. PubMed ID: 12089723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations in hormonal receptor expression and HER2 status between primary breast tumors and paired nodal metastases: discordance rates and prognosis.
    Ba JL; Liu CG; Jin F
    Asian Pac J Cancer Prev; 2014; 15(21):9233-9. PubMed ID: 25422206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Male occult breast cancer with axillary lymph node metastasis as the first manifestation: A case report and literature review.
    Xu R; Li J; Zhang Y; Jing H; Zhu Y
    Medicine (Baltimore); 2017 Dec; 96(51):e9312. PubMed ID: 29390502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic immunohistochemistry of cutaneous metastatic breast carcinoma: a statistical analysis of the utility of gross cystic disease fluid protein-15 and estrogen receptor protein.
    Ormsby AH; Snow JL; Su WP; Goellner JR
    J Am Acad Dermatol; 1995 May; 32(5 Pt 1):711-6. PubMed ID: 7722013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic adenocarcinoma to the brain: an immunohistochemical approach.
    Perry A; Parisi JE; Kurtin PJ
    Hum Pathol; 1997 Aug; 28(8):938-43. PubMed ID: 9269830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Axillary nodal metastasis of occult breast primary cancer.
    Tamiolakis D; Antoniou C
    Chirurgia (Bucur); 2008; 103(4):467-71. PubMed ID: 18780622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen and gross cystic disease fluid protein-15 are co-expressed in androgen receptor-positive breast tumours.
    Hall RE; Clements JA; Birrell SN; Tilley WD
    Br J Cancer; 1998 Aug; 78(3):360-5. PubMed ID: 9703283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.